Home/Filings/4/0001415889-24-009249
4//SEC Filing

Segal Lloyd Mitchell 4

Accession 0001415889-24-009249

CIK 0001808158other

Filed

Mar 26, 8:00 PM ET

Accepted

Mar 27, 6:54 PM ET

Size

10.4 KB

Accession

0001415889-24-009249

Insider Transaction Report

Form 4
Period: 2024-03-25
Segal Lloyd Mitchell
DirectorPRESIDENT AND CEO
Transactions
  • Sale

    Common Shares

    2024-03-26$4.64/sh2,650$12,29686,516 total(indirect: See footnote)
  • Sale

    Common Shares

    2024-03-25$4.79/sh2,650$12,69489,166 total(indirect: See footnote)
  • Sale

    Common Shares

    2024-03-27$4.63/sh2,650$12,27083,866 total(indirect: See footnote)
Holdings
  • Common Shares

    124,677
Footnotes (5)
  • [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 22, 2023. On January 30, 2023, the holder was granted 78,550 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on February 1, 2023, of which 26,183 of these RSUs vested on January 30, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.72 to $4.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4) and (5).
  • [F3]These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the "Company"). The Reporting Person is the sole stockholder of the Company.
  • [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.52 to $4.83 inclusive.
  • [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.52 to $4.77 inclusive.

Issuer

Repare Therapeutics Inc.

CIK 0001808158

Entity typeother

Related Parties

1
  • filerCIK 0001477123

Filing Metadata

Form type
4
Filed
Mar 26, 8:00 PM ET
Accepted
Mar 27, 6:54 PM ET
Size
10.4 KB